Tevogen Bio Announces Up to $50 Million in Financing to Further Advance Operational Objectives [Yahoo! Finance]
Tevogen Bio Holdings Inc. (TVGN)
Company Research
Source: Yahoo! Finance
WARREN, N.J., May 10, 2024 (GLOBE NEWSWIRE) -- Tevogen Bio Holdings Inc. (“Tevogen” or “Tevogen Bio”) (Nasdaq: TVGN ), a clinical-stage specialty immunotherapy biotech pioneer developing off-the-shelf, genetically unmodified T cell therapeutics in oncology, neurology, and virology, has entered into a binding term sheet [with an existing investor] to secure up to $50 million of financing. This financing supports Tevogen Bio's pursuit of expanding research and development efforts with a focus on continued clinical development of the company's initial product, TVGN 489, from its ExacTcell technology platform. In January 2023, Tevogen Bio announced positive proof-of-concept clinical trial results of TVGN 489 for treatment of high-risk patients. The financing will also be utilized to facilitate Tevogen Bio's efforts to start additional clinical trials for virally induced cancers and multiple sclerosis. “The financing will help us to pursue our goals and we are gratified by the support
Show less
Read more
Impact Snapshot
Event Time:
TVGN
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
---|---|---|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
Last Price | ||
VWAP | ||
High:
|
Max Up |
High:
|
Low:
|
Max Down |
Low:
|
%
|
Post news range |
%
|
|
Price change |
|
|
Price Change Percentage |
|
|
S&P 500 (SPX) |
|
%
|
Volume ratio |
%
|
Volume | ||
Ticks | ||
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
TVGN alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
TVGN alerts
High impacting Tevogen Bio Holdings Inc. news events
Weekly update
A roundup of the hottest topics
TVGN
News
- Tevogen Bio Leadership Meets Members of U.S. Congress to Advocate for Long COVID Patients and Highlights Achievements and Assets as a Blueprint for Biotech InnovationGlobeNewswire
- Tevogen Bio Secures $6 Million Series C Preferred Stock InvestmentGlobeNewswire
- CORRECTION – Tevogen Bio Reports Second Quarter 2024 Financial Results, Eliminates Doubt About Company's Ability to Continue as a Going Concern, Eliminates Series B Preferred Shares [Yahoo! Finance]Yahoo! Finance
- CORRECTION – Tevogen Bio Reports Second Quarter 2024 Financial Results, Eliminates Doubt About Company’s Ability to Continue as a Going Concern, Eliminates Series B Preferred SharesGlobeNewswire
- Tevogen Bio Reports Second Quarter 2024 Financial Results, Eliminates Doubt About Company’s Ability to Continue as a Going Concern, Eliminates Series B Preferred SharesGlobeNewswire
TVGN
Sec Filings
- 8/26/24 - Form 424B3
- 8/26/24 - Form 8-K/A
- 8/23/24 - Form 424B3
- TVGN's page on the SEC website